NCT05131464

The Study of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps

An Open-label, Single-arm, Multicenter, Extension Study to Evaluate the Long-term Safety and Efficacy of CM310 in Patients With Chronic Rhinosinusitis With Nasal Polyps

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (actual)
• Sponsor: Keymed Biosciences Co.Ltd · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is an open-label, single-arm, multicenter, extension study to evaluate the long-term safety and efficacy of CM310 in patients with CRSwNP.

Conditions

• Chronic Rhinosinusitis With Nasal Polyps

Interventions

Type	Name	Description
DRUG	CM310	CM310, 300 mg/2 mL, SC, every 2 weeks

Timeline

• Start date: 2021-11-30
• Primary completion: 2024-01-31
• Completion: 2024-01-31
• First posted: 2021-11-23
• Last updated: 2024-11-08

Locations

3 sites across 1 country: China